Could Insulin Resistance Be Driving Treatment-Resistant Depression? And How EXOMIND TMS Might Help

By Andrew J Hewitt, PMHNP-BC Abstract Treatment-resistant depression (TRD) remains a formidable clinical challenge. Emerging evidence suggests that metabolic dysregulation—particularly insulin resistance (IR)—may underlie or perpetuate depressive states unresponsive to standard therapies. This blog reviews recent evidence linking IR to antidepressant nonresponse, explores possible mechanistic pathways (neuroinflammation, blood–brain barrier dysfunction, neurotransmitter dysregulation), and describes how EXOMIND […]